ClinicalTrials.gg
Active, not recruitingNCT05077774Updated Oct 1, 2026

Harmony TPV Post-Approval Study

An interventional study of Harmony TPV System in Congenital Heart Disease, Tetrology of Fallot and RVOT Anomaly, sponsored by Medtronic Cardiovascular. Active, not recruiting at 20 sites in 2 countries. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Medtronic Cardiovascular (part of Medtronic) · Not applicable, Interventional, and Treatment

Updated Oct 1, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
174
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 356 studies in Heart Defects, Congenital with a site in United States — 67 open to participants now, 88 under way, 4 of them phase 3. Heart Defects, Congenital · United States.

Enrollment
30th of 184
174 · median 50
Started
2021
with 18 others
No phase
111 of 356
22 open now
Primary completion
2026-11
later than 23 of 87 live
Registered
278th of 356
by date

Among the 356 studies in Heart Defects, Congenital with a site in United States, this one is the 30th largest by enrollment of the 184 interventional ones that give a count, is one of 19 that started in 2021, is one of 111 with no phase, reaches primary completion later than 23 of the 87 other live ones, and was the 278th registered.

Heart Defects, Congenital

992 studies on the registry are indexed under Heart Defects, Congenital; 253 are open to participants now.

Browse Heart Defects, Congenital studies →

Open to participants now

67 of the 356 studies in Heart Defects, Congenital with a site in United States are open now. Recruiting first, the newest first:

62 more — sign in →

All 67 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 155 Heart Defects, Congenital studies recruiting now, 67 (43%) set no upper age limit and 80 (52%) stop at 75 or younger; 111 take children under 18; 25 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 356 studies in Heart Defects, Congenital with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to characterize the functionality of transcatheter implantation of the Medtronic Harmony Transcatheter Pulmonary Valve (TPV) achieved by real-world implanters.

03

Conditions studied

  • Congenital Heart Disease
  • Tetrology of Fallot
  • RVOT Anomaly
  • Pulmonary Regurgitation
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient eligible to receive the Harmony TPV, meeting the indications for use criteria per current geography-specific device labeling at time of study enrollment
  • Patient (or patient's legally authorized representative) is willing to consent to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Obstruction of the central veins
  • Planned concomitant branch pulmonary artery stenting at time of implant
  • Subject is pregnant at time of implant procedure
  • Patients with previously treated with an RV-PA conduit or previously implanted bioprosthesis
  • A major or progressive non-cardiac disease (e.g. liver failure, renal failure, cancer) that results in a of less than one year
  • Planned implantation of the Harmony TPV in the left heart
  • Echocardiographic evidence of intracardiac mass, thrombus, or vegetation
  • Pre-existing prosthetic heart valve or prosthetic ring in any position
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
174 participants (actual)

Study arms

  • Other
    Harmony TPV System

    Intervention Device: Harmony Transcatheter Pulmonary Valves and Delivery System

    Device: Harmony TPV System

Interventions

  • DeviceHarmony TPV System

    Harmony Transcatheter Pulmonary Valve (sizes 22 mm and 25 mm) and Harmony Delivery Catheter System (DCS)

    Also known as: Model Numbers: HARMONY-22, HARMONY-25, and HARMONY-DCS

06

What researchers measure

Primary outcomes

  1. Proportion of subjects without valve reintervention and with acceptable hemodynamic function composite at 6 months as defined by:

    * Mean RVOT gradient as measured by continuous-wave Doppler echocardiography ≤40 mmHg AND * Pulmonary regurgitant fraction as measured by CMR \<20%

    Time frame: 6 months

Secondary outcomes

  1. Percentage of subjects free from all-cause mortality at 6-months

    Described by Kaplan-Meier statistics at 6-months.

    Time frame: 6 months

  2. Percentage of subjects free from reoperation at 6-months

    Described by Kaplan-Meier statistics at 6-months.

    Time frame: 6 months

  3. Percentage of subjects free from catheter reintervention at 6-months

    Described by Kaplan-Meier statistics at 6-months.

    Time frame: 6 months

  4. Percentage of subjects free from TPV dysfunction at 6-months

    Described by Kaplan-Meier statistics at 6-months.

    Time frame: 6 months

  5. Number and percentage of subjects with procedure success at 30-days

    Time frame: 30-days

  6. Number and percentage of subjects with serious device-related adverse events at 6 months

    Also described with Kaplan-Meier method for AEs of clinical interest.

    Time frame: 6 months

07

Study locations

20 sites
08

References and documents

Publications

  • Gillespie MJ, McElhinney DB, Jones TK, Levi DS, Asnes J, Gray RG, Cabalka AK, Fujimoto K, Qureshi AM, Justino H, Bergersen L, Benson LN, Haugan D, Boe BA, Cheatham JP. 1-Year Outcomes in a Pooled Cohort of Harmony Transcatheter Pulmonary Valve Clinical Trial Participants. JACC Cardiovasc Interv. 2023 Aug 14;16(15):1917-1928. doi: 10.1016/j.jcin.2023.03.002. Epub 2023 May 17. PubMed 37278682 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2021 (actual). Primary completion is estimated for Nov 2026, 61 months after the start.

Of 224 interventional studies with no phase under Heart Defects, Congenital, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 57. This study's planned 61 months is above that.

Primary completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → Nov 2026, on Oct 1, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2021
First posted
Oct 14, 2021
StartActual
Oct 25, 2021
Primary completionEst.
Nov 2026was Aug 2026
CompletionEst.
Mar 2035
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 2026→Nov 2026
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Primary completion Aug 2026→Nov 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05077774
Responsible party
Sponsor
First posted
Oct 14, 2021
Start date
Oct 25, 2021
Primary completion
Nov 2026 (estimated)
Completion
Mar 2035 (estimated)
Last update
Oct 1, 2026

Study contacts

David Balzer, MD
principal investigator · St. Louis Children's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion